Search

everythinglearnresearchcommunity

for

Search:↓

Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

Aromatase inhibitor therapy for breast cancer increases the risk of hair loss and thinning.

Two teenage boys lost hair after taking a drug for growth, which was not a known side effect for kids.

Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.

Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

New treatments for PCOS focus on insulin resistance and reducing testosterone levels, along with traditional hormone therapies.

Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

Low-dose oral minoxidil improved hair growth when topical treatments failed.

Intravaginal testosterone cream improves sexual satisfaction and reduces vaginal discomfort in postmenopausal women on breast cancer treatment without affecting hormone levels.

Hair regrowth treatments had modest benefits for patients with long-term hair loss after chemotherapy.

Certain drugs can worsen hair loss in people prone to androgenetic alopecia.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

Female pattern hair loss diagnosed by scalp appearance, treated with combined therapies and targeted approaches.

Juniperus plants contain compounds with potential for developing various medical treatments.

The new drug delivery system improves exemestane's absorption and effectiveness.

Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.

Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.

Docetaxel chemotherapy causes more long-term hair loss and dissatisfaction than paclitaxel.

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

Adjuvants, diet changes, and laser therapy may improve male pattern hair loss.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.